MedTrace Logo

A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC

NCT05319431 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-03-12

No results posted yet for this study

Summary

To evaluate the efficacy and safety of AK104 plus lenvatinib combined with on-demand TACE in participants with unresectable, non-metastatic hepatocellular carcinoma

Conditions

  • Unresectable, Non-metastatic Hepatocellular Carcinoma

Interventions

BIOLOGICAL

AK104

Subjects will receive AK104 until disease progression or for a maximum of 24 months

DRUG

Lenvatinib

Subjects will receive lenvatinib until disease progression or for a maximum of 24 months

PROCEDURE

TACE

On demand TACE

Sponsors & Collaborators

Principal Investigators

  • Guoliang Shao, MD · Zhejiang Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-28
Primary Completion
2023-08-15
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05319431 on ClinicalTrials.gov